Minakem Generic APIs Minakem Generic APIs

X
[{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Essential Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Essential Pharma Announces the Acquisition of Reminyl\u00ae (galantamine hydrobromide) Oral Capsules","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"April 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals for Galantamine Hydrobromide

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Under the acquisition, Essential Pharma has acquired rights to Reminyl (galantamine hydrobromide), a cholinesterase inhibitor, oral capsules in the EEA, Thailand, South Korea and all other current markets for that product, excluding UK and Ireland, Japan and Latin America.

            Lead Product(s): Galantamine Hydrobromide

            Therapeutic Area: Neurology Product Name: Reminyl

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Essential Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition April 17, 2024

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY